Trump Nominates New FDA Commissioner
This content is restricted to AAHP members. If you are a member, please login. If you are not a member, click here.Existing Users Log InUsername or EmailPassword Remember Me
Why It’s Crucial to Monitor FDA Guidances
By Mark Land, AAHP President It can take several years for manufacturers to implement new guidelines from the Food and Drug Administration (FDA)—and that means they could be at risk in the meantime. However, manufacturers can “get ahead of the game” by monitoring FDA’s guidance development agenda. FDA’s authority to regulate stems from the Federal…
Australia to Release the First Draft Report on Homeopathy Effectiveness
By Mark Land, AAHP President Many believe the draft report arrived at a more encouraging conclusion regarding the effectiveness of homeopathy and may have been suppressed by the then conservative Australian government. After years of requests and inquiry, Australia’s National Health and Medical Research Council (NHMRC) has decided to release the first draft report.…
2020 Democratic Presidential Run
By Pete Evich, AAHP Government Relations As the 2020 U.S. presidential election inches closer, many Democratic hopefuls have launched campaigns to take the White House. At AAHP, we are keeping a close eye on the candidates and proposed policies that could affect the homeopathic industry. Here is an overview of key candidates and the…
Summit Photos: Experience the Excitement
The AAHP community is still abuzz from all the excitement, networking, and learning that took place at last month’s Quality and Safety Summit in Baltimore! Between the opening reception and following day of sessions, we hosted more than 100 people from five countries across the globe. With a keynote session from Francis Godwin of the…
A First Look at AAHP Summit Speakers
We are thrilled to offer a first look at the speakers and sessions for our upcoming Summit on Challenges and Solutions in Quality & Safety of Homeopathic Drug Products! This unique one-day workshop is designed to help you manufacture safe products while complying within FDA and FTC guidelines. Some of the workshops included in the…
How to Work with FDA on Voluntary Recalls
This content is restricted to AAHP members. If you are a member, please login. If you are not a member, click here.Existing Users Log InUsername or EmailPassword Remember Me
Initiation of Voluntary Recalls: Draft Guidance for Industry and FDA Staff
By Mark Land, AAHP President Product recalls are an important tool that manufacturers and the U.S. Food and Drug Administration (FDA) use to minimize exposure to potentially harmful or ineffective products.1 Drug product recalls are voluntary — that is to say, FDA does not have legal authority to recall a drug product. They do,…
Overview: Membership Meeting 2019
The membership of AAHP came together on March 8 for the association’s semiannual Membership Meeting. Taking place during Natural Products Expo West in Anaheim, Calif., AAHP members convened to hear updates on projects and initiatives, network, and elect new leadership before hitting the tradeshow floor. Three-Pronged Strategic Approach for 2019 AAHP president Mark Land kicked…
Reduce Risk with Product Substantiation
When bringing products to market, it is essential to build a platform that allows all information generated to be available for future use,” advised Susan J. Hewlings, PhD, RD, during a preview for her workshop this June at the AAHP Summit in Baltimore. Guest speaker at AAHP’s March 8 Membership Meeting during Natural Products…
AAHP monitors and reports on current federal regulations, legislation and government policies that affect the homeopathic community. AAHP is often the first to learn of regulatory changes that have both direct and indirect effects on our industry enabling members to stay ahead of the curve in a rapidly changing healthcare environment.